Nuvectis Pharma Inc. (NASDAQ: NVCT) reported its full‑year 2025 financial results, posting a net loss of $26.4 million versus a $19.0 million loss in 2024. The larger loss was driven by $6.0 million in non‑cash stock‑based compensation and a one‑time $2.4 million license fee that was triggered by a milestone in the NXP900 Phase 1b program. The company’s Q3 2025 net loss of $7.5 million, R&D expenses of $5.8 million and G&A costs of $2.0 million provide a quarterly context for the year‑over‑year decline.
Cash and cash equivalents rose to $31.6 million at year‑end, up from $18.5 million in 2024. The increase was largely the result of a February 2025 public offering that raised approximately $15.5 million and proceeds from the at‑the‑market facility. The stronger cash position is expected to support the company’s clinical program through the third quarter of 2027.
Research and development expenses climbed to $18.2 million, reflecting continued investment in the NXP900 pipeline, while general and administrative costs increased to $9.4 million. The higher operating expenses are consistent with the company’s strategy of accelerating clinical development in the absence of product revenue.
NXP900, an oral SRC/YES1 kinase inhibitor, entered Phase 1b monotherapy and combination studies with osimertinib and lorlatinib. Enrollment is underway, and the company has halted development of its other candidate, NXP800, after a Phase 1b study revealed thrombocytopenia. CEO Ron Bentsur said, “2025 was an eventful year for Nuvectis, with significant progress made in the NXP900 development program, laying the groundwork for multiple potential data readouts in 2026.”
Bentsur also emphasized operational execution and financial responsibility, noting that the current cash runway should carry the company through multiple Phase 1b milestones and well into the second half of 2027. The company’s focus remains on advancing NXP900, with expectations that 2026 will deliver key data that could position the drug to address resistance to existing therapies in non‑small cell lung cancer.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.